Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country. A randomized control trial

Ainuddin, Jahanara; Karim, Nasim; Hasan, Anjum; Naqvi, Sanower Ali

doi:10.1016/j.diabres.2014.10.001

Cited by 77 publications

(107 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However Ainuddin et al found a mean weight gain of 9.8±1.5 Kg in metformin group and 12.5±1.1 Kg in insulin group, the difference being statistically significant (P<0.0001). 2 Niromanesh et al also found significant weight gain 13.7±3.1 in insulin versus 11.3±3.8 in metformin group. 3 Other studies also found similar results and suggested that metformin has a beneficial effect on the weight of mothers.…”

Section: Resultsmentioning

confidence: 94%

“…Reduction in neonatal weight after use of metformin has been reported by some studies. [2][3][4][5] But some studies have documented normal weight of neonates after metformin therapy.…”

Section: Introductionmentioning

confidence: 99%

“…1,2 The incidence of GDM depends on the diagnostic criterion and varies widely in different racial groups. Various studies have shown a wide range of incidence of about 1% to 14%.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Metformin Vs Insulin for Treatment of Gestational Diabetes-A Randomized Clinical Trial

Pranathi¹,

Devi

2018

ijmsci

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 94%

“…Reduction in neonatal weight after use of metformin has been reported by some studies. [2][3][4][5] But some studies have documented normal weight of neonates after metformin therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Metformin Vs Insulin for Treatment of Gestational Diabetes-A Randomized Clinical Trial

Pranathi¹,

Devi

2018

ijmsci

View full text Add to dashboard Cite

“…После исследования MIG было опубликовано мно-жество РКИ, посвященных сравнению метформина с инсулином, которые в большинстве своем подтвердили данные MIG [16][17][18][19][20][21][22][23]. Единственным ключевым отли-чием стало отсутствие тенденции к преждевременному родоразрешению в группе пациенток на метформине, которое было показано в MIG.…”

Section: репродуктивное здоровьеunclassified

“…Одно из исследований (Ainuddin J., и соавт.) [22] продемонстрировало сниже-ние риска развития преэклампсии, что опровергло ранее полученные результаты Hellmuth Е. и соавт., которые вы-зывали много вопросов у клиницистов (табл. 1).…”

Section: репродуктивное здоровьеunclassified

Efficacy and safety of metformin for the treatment of gestational diabetes: a new approach to the problem

Сазонова¹,

Esayan²,

Kolegaeva³

et al. 2016

Diabetes mellitus

View full text Add to dashboard Cite

Репродуктивное здоровьеReproductive Health ыбор лекарственных препаратов во время бере-менности всегда представляет сложную задачу, в основном, вследствие морально-этических аспектов. Вместе с тем, в последние десятилетия расши-рился круг соматических заболеваний, при которых стало возможным наступление и пролонгирование беремен-ности. Среди эндокринной патологии одна из наиболее часто встречающихся проблем во время беременно-сти -это гипергликемия. По данным Международной Диабетической Федерации, каждый шестой новорож-денный (16,8%) появляется на свет у женщины с гипер-гликемией во время беременности. Всего 16% из этих случаев приходится на предшествующий беременности сахарный диабет 1 или 2 типа, в то время как большин-Эффективность и безопасность применения препаратов метформина при беременности для лечения гестационного сахарного диабета: современный взгляд на проблему © Сазонова А.И., Есаян Р.М., Колегаева О.И., Гарданова Ж.Р. (FIGO, 2015) and new opportunities for gestational diabetes mellitus treatment. ФГБУ

show abstract

Insulin for the treatment of women with gestational diabetes

Brown

Grzeskowiak

Williamson

et al. 2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

The main comparison in this review is insulin versus oral anti-diabetic pharmacological therapies. Insulin and oral anti-diabetic pharmacological therapies have similar effects on key health outcomes. The quality of the evidence ranged from very low to moderate, with downgrading decisions due to imprecision, risk of bias and inconsistency.For the other comparisons of this review (insulin compared with non-pharmacological interventions, different insulin analogies or different insulin regimens), there is insufficient volume of high-quality evidence to determine differences for key health outcomes.Long-term maternal and neonatal outcomes were poorly reported for all comparisons.The evidence suggests that there are minimal harms associated with the effects of treatment with either insulin or oral anti-diabetic pharmacological therapies. The choice to use one or the other may be down to physician or maternal preference, availability or severity of GDM. Further research is needed to explore optimal insulin regimens. Further research could aim to report data for standardised GDM outcomes.

show abstract

Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country. A randomized control trial

Cited by 77 publications

References 27 publications

Metformin Vs Insulin for Treatment of Gestational Diabetes-A Randomized Clinical Trial

Metformin Vs Insulin for Treatment of Gestational Diabetes-A Randomized Clinical Trial

Efficacy and safety of metformin for the treatment of gestational diabetes: a new approach to the problem

Insulin for the treatment of women with gestational diabetes

Contact Info

Product

Resources

About